Koers Mabvax Therapeutics Holdings Inc Other OTC
Aandelen
US55414P7024
Biotechnologie & Medisch Onderzoek
Omzet 2016 | 148K 138K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,41 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,82 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,68 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 437K | Nettoschuld 2017 | 2,48 mln. 2,31 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,44% | 122 mld. | |
+18,94% | 114 mld. | |
+19,62% | 25,71 mld. | |
-25,37% | 19,02 mld. | |
-20,21% | 15,83 mld. | |
-20,20% | 15,32 mld. | |
-47,37% | 14,88 mld. | |
+59,91% | 14,82 mld. | |
+4,35% | 14,1 mld. |